Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Efficacy and safety of antidepressant augmentation of continued antipsychotic treatment in patients with schizophrenia
Britta Galling, Jeffrey A. Vernon, Anne Katrine Pagsberg, et al.
Acta Psychiatrica Scandinavica (2018) Vol. 137, Iss. 3, pp. 187-205
Closed Access | Times Cited: 72

Showing 1-25 of 72 citing articles:

<p>Negative Symptoms in Schizophrenia: A Review and Clinical Guide for Recognition, Assessment, and Treatment</p>
Christoph U. Correll, Nina R. Schooler
Neuropsychiatric Disease and Treatment (2020) Vol. Volume 16, pp. 519-534
Open Access | Times Cited: 555
Evidence-based guidelines for the pharmacological treatment of schizophrenia: Updated recommendations from the British Association for Psychopharmacology
Thomas R. E. Barnes, Richard Drake, Carol Paton, et al.
Journal of Psychopharmacology (2019) Vol. 34, Iss. 1, pp. 3-78
Open Access | Times Cited: 509
The neurobiology of treatment-resistant schizophrenia: paths to antipsychotic resistance and a roadmap for future research
Steven G. Potkin, John M. Kane, Christoph U. Correll, et al.
Schizophrenia (2020) Vol. 6, Iss. 1
Open Access | Times Cited: 282
EPA guidance on treatment of negative symptoms in schizophrenia
Silvana Galderisi, Stefan Kaiser, István Bitter, et al.
European Psychiatry (2021) Vol. 64, Iss. 1
Open Access | Times Cited: 135
Pathophysiology of negative symptom dimensions of schizophrenia – Current developments and implications for treatment
Indrit Bègue, Stefan Kaiser, Matthias Kirschner
Neuroscience & Biobehavioral Reviews (2020) Vol. 116, pp. 74-88
Open Access | Times Cited: 92
Clozapine Combination and Augmentation Strategies in Patients With Schizophrenia —Recommendations From an International Expert Survey Among the Treatment Response and Resistance in Psychosis (TRRIP) Working Group
Elias Wagner, John M. Kane, Christoph U. Correll, et al.
Schizophrenia Bulletin (2020) Vol. 46, Iss. 6, pp. 1459-1470
Open Access | Times Cited: 87
Pimavanserin for negative symptoms of schizophrenia: results from the ADVANCE phase 2 randomised, placebo-controlled trial in North America and Europe
Dragana Bugarski‐Kirola, Celso Arango, Maurizio Fava, et al.
The Lancet Psychiatry (2021) Vol. 9, Iss. 1, pp. 46-58
Closed Access | Times Cited: 59
Negative symptoms in children and adolescents with early-onset psychosis and at clinical high-risk for psychosis: systematic review and meta-analysis
Gonzalo Salazar de Pablo, Ana Catalán, Julio Vaquerizo Serrano, et al.
The British Journal of Psychiatry (2023) Vol. 223, Iss. 1, pp. 282-294
Open Access | Times Cited: 25
An umbrella review of candidate predictors of response, remission, recovery, and relapse across mental disorders
Marco Solmi, Samuele Cortese, Giovanni Vita, et al.
Molecular Psychiatry (2023) Vol. 28, Iss. 9, pp. 3671-3687
Open Access | Times Cited: 25
Psychosis superspectrum II: neurobiology, treatment, and implications
Roman Kotov, William T. Carpenter, David C. Cicero, et al.
Molecular Psychiatry (2024) Vol. 29, Iss. 5, pp. 1293-1309
Closed Access | Times Cited: 9
Developments in Biological Mechanisms and Treatments for Negative Symptoms and Cognitive Dysfunction of Schizophrenia
Qiongqiong Wu, Xiaoyi Wang, Ying Wang, et al.
Neuroscience Bulletin (2021) Vol. 37, Iss. 11, pp. 1609-1624
Open Access | Times Cited: 41
Risk factors, prevention and treatment of weight gain associated with the use of antidepressants and antipsychotics: a state-of-the-art clinical review
Marco Solmi, Alessandro Miola, Federico Capone, et al.
Expert Opinion on Drug Safety (2024) Vol. 23, Iss. 10, pp. 1249-1269
Closed Access | Times Cited: 6
Antidepressant tapering strips to help people come off medication more safely
Peter C. Groot, Jim van Os
Psychosis (2018) Vol. 10, Iss. 2, pp. 142-145
Open Access | Times Cited: 52
Treatment resistant schizophrenia – review and a call to action
John Lally, Fiona Gaughran
Irish Journal of Psychological Medicine (2018) Vol. 36, Iss. 4, pp. 279-291
Open Access | Times Cited: 51
Comparative Effectiveness of Adjunctive Psychotropic Medications in Patients With Schizophrenia
T. Scott Stroup, Tobias Gerhard, Stephen Crystal, et al.
JAMA Psychiatry (2019) Vol. 76, Iss. 5, pp. 508-508
Open Access | Times Cited: 45
Prescription of antipsychotic and concomitant medications for adult Asian schizophrenia patients: Findings of the 2016 Research on Asian Psychotropic Prescription Patterns (REAP) survey
Min Dong, Liang-Nan Zeng, Qinge Zhang, et al.
Asian Journal of Psychiatry (2019) Vol. 45, pp. 74-80
Closed Access | Times Cited: 44
Clozapine resistant schizophrenia: Newer avenues of management
Subho Chakrabarti
World Journal of Psychiatry (2021) Vol. 11, Iss. 8, pp. 429-448
Open Access | Times Cited: 36
Conceptualization and characterization of “primary” and “secondary” cognitive impairment in schizophrenia
Antonio Vita, Gabriele Nibbio, Sergio Barlati
Psychiatry Research (2024) Vol. 340, pp. 116126-116126
Open Access | Times Cited: 5
MDMA for the Treatment of Negative Symptoms in Schizophrenia
Mitchell Arnovitz, Andrew J. Spitzberg, Ashkhan J. Davani, et al.
Journal of Clinical Medicine (2022) Vol. 11, Iss. 12, pp. 3255-3255
Open Access | Times Cited: 22
Adjunctive agents to antipsychotics in schizophrenia: a systematic umbrella review and recommendations for amino acids, hormonal therapies and anti-inflammatory drugs
Guillaume Fond, Jasmina Mallet, Mathieu Urbach, et al.
BMJ Mental Health (2023) Vol. 26, Iss. 1, pp. e300771-e300771
Open Access | Times Cited: 12
Risperidone Decreases Expression of Serotonin Receptor-2A (5-HT2A) and Serotonin Transporter (SERT) but Not Dopamine Receptors and Dopamine Transporter (DAT) in PBMCs from Patients with Schizophrenia
Samantha Álvarez-Herrera, Mauricio Rosel-Vales, Gilberto Pérez‐Sánchez, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 2, pp. 167-167
Open Access | Times Cited: 4
Treatment and long-term outcome of mental disorders: the grim picture from a quasi-epidemiological investigation in 54,826 subjects from 40 countries
Konstantinos Ν. Fountoulakis, Grigorios N. Karakatsoulis, Seri Abraham, et al.
Psychiatry Research (2025), pp. 116459-116459
Open Access
Schizophrenia and Related Psychoses

(2025), pp. 1-278
Closed Access
Treatment of pharmacoresistant states in psychiatry - Part 1: Treatment-resistant schizophrenia
Eva Češková
Psychiatrie pro praxi (2025) Vol. 26, Iss. 1, pp. 10-14
Closed Access
Sex and age effects on prevalence of CYP2C19 and CYP2D6 Phenoconversion risk over time in patients with psychosis
Emma Y De Brabander, Nicole Leibold, Thérèse van Amelsvoort, et al.
Progress in Neuro-Psychopharmacology and Biological Psychiatry (2025), pp. 111363-111363
Closed Access
Page 1 - Next Page

Scroll to top